keyword
MENU ▼
Read by QxMD icon Read
search

PTLD

keyword
https://www.readbyqxmd.com/read/29666729/posttransplant-lymphoproliferative-disorder-presenting-as-testicular-lymphoma-in-a-kidney-transplant-recipient-a-case-report-and-review-of-the-literature
#1
Steve Omoruyi Obanor, Michelle Gruttadauria, Kayla Applebaum, Mohammad Eskandari, Michelle Lieberman Lubetzky, Stuart Greenstein
Posttransplant lymphoproliferative disorder (PTLD) is a malignancy caused by the immunosuppression that occurs after transplantation. It is primarily a nodal lesion but frequently it involves extranodal masses. Treatment is usually by reducing immunosuppressive therapy. Testicular lymphoma as PTLD is notably rare in documented literature and there is limited evidence of definitive treatment guidelines. This manuscript describes a patient who developed diffuse large B-cell lymphoma of his right testis one year following kidney transplantation...
2018: Case Reports in Nephrology
https://www.readbyqxmd.com/read/29665928/-clinical-characteristics-treatment-and-prognosis-of-ptld-after-allogeneic-hematopoietic-stem-cell-transplantation
#2
Zhan-Xiang Liu, Wen-Rong Huang, Meng Li, Zhen-Yang Gu, Cheng-Ying Zhu, Ning Lu, Sheng Yao, Shu-Hong Wang, Fei Li, Xiao-Ning Gao, Dai-Hong Liu, Chun-Ji Gao
OBJECTIVE: To study the clinical characteristics of patients with post-transplantation lymphoproliferative disease (PTLD) after allogeneic peripheral blood hematopoietic stem cell transplantation, and to improve the understanding and diagnosis of PTLD. METHODS: The clinical data of 244 patients underwent allogeneic hematopoietic stem cell transplantation in the General Hospital of PLA from May 2014 to April 2017 were analyzed retrospectively. The follow-up time was up to November 30, 2017...
April 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29661457/progressive-multifocal-leukoencephalopathy-following-combined-rituximab-based-immune-chemotherapy-for-post-transplant-lymphoproliferative-disorder-in-a-renal-transplant-recipient-a-case-report
#3
M Windpessl, S Burgstaller, A Kronbichler, H Pieringer, O Kalev, A Karrer, M Wallner, J Thaler
BACKGROUND: Transplant recipients are at risk of developing progressive multifocal leukoencephalopathy (PML), an opportunistic infection due to reactivation of JC virus. Post-transplant lymphoproliferative disorders (PTLDs) represent a common malignancy in this population, and antiCD20-therapy has become an established component of its treatment. CASE PRESENTATION: We describe the first case of a renal allograft transplant recipient with PTLD who received rituximab-based immune-chemotherapy and developed PML shortly thereafter...
April 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29661453/late-onset-post-transplantation-central-nervous-system-lymphoproliferative-disorder-case-report
#4
J Rego Silva, R A Macau, H Oliveira Coelho, F Camelo, P Cruz, A Mateus, A Oliveira, C Oliveira, A Ramos
Post-transplantation lymphoproliferative disorder (PTLD) is a heterogeneous group of conditions that complicate organ transplantation and are due to immunosuppression. Central nervous system (CNS)-PTLD is rare but its incidence is increasing. It often occurs late and is associated with kidney transplantation and Epstein-Barr virus (EBV) infection. Outcomes are poor. We present the case of a 77-year-old white male who received a cadaveric kidney transplant in 2003. Maintenance immunosuppression consisted of mycofenolate mofetil (MMF), cyclosporine, and prednisolone...
April 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29659047/the-changing-face-of-adult-posttransplant-lymphoproliferative-disorder-changes-in-histology-between-1999-2013
#5
Donald E Tsai, Stephen Bagley, Ran Reshef, Abraham Shaked, Roy D Bloom, Vivek Ahya, Lee Goldberg, Albert Chung, Fotini Debonera, Stephen J Schuster, Scott F Huntington
Posttransplant lymphoproliferative disorder (PTLD) typically presents with either polymorphic or monomorphic histology. While both are the end result of immunosuppressive therapies, their origins are felt to be different with different prognoses and responsiveness to therapy, resulting in two different malignancies. We attempted to confirm reports suggesting that the relative frequency of these two histologies is shifting over time. We analyzed 3040 adult PTLD cases in the UNOS OPTN database from 1999 to 2013...
April 16, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29642526/construction-and-characterization-of-a-humanized-anti-epstein-barr-virus-gp350-antibody-with-neutralizing-activity-in-cell-culture
#6
Jerome E Tanner, Jing Hu, Caroline Alfieri
Acute Epstein-Barr virus (EBV) infection in immunosuppressed transplant patients can give rise to a malignant B-cell proliferation known as post-transplant lymphoproliferative disease (PTLD). The EBV major virion surface glycoprotein (gp)350 is a principal target of naturally occurring neutralizing antibodies and is viewed as the best target to prevent acute infection and PTLD in at-risk transplant recipients. We have constructed a humanized (hu) version of the murine anti-gp350 neutralizing monoclonal antibody 72a1...
April 9, 2018: Cancers
https://www.readbyqxmd.com/read/29620685/ebv-ptld-adenovirus-and-cmv-in-pediatric-allogeneic-transplants-with-alemtuzumab-as-part-of-pretransplant-conditioning-a-retrospective-single-center-study
#7
Margaret C Cupit-Link, Amulya Nageswara Rao, Deepti M Warad, Vilmarie Rodriguez, Shakila Khan
The risk of viral infections and reactivation occurring in the setting of pediatric allogeneic hematopoietic stem cell transplantation is a concern in the pediatric patient, especially with the use of Alemtuzumab (Campath) as a conditioning agent. The purpose of this study was to determine the incidence of Epstein-Barr virus posttransplant lymphoproliferative disorder (EBV-PTLD), cytomegalovirus (CMV), and adenovirus among pediatric recipients of alemtuzumab at our institution. We found that EBV-PTLD occurred in 2...
April 3, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29615296/reexamining-post-transplant-lymphoproliferative-disorders-newly-recognized-and-enigmatic-types
#8
REVIEW
Nadine Aguilera, Alejandro A Gru
Post-transplant lymphoproliferative disorders (PTLD) are a known risk for both solid organ transplant and stem cell transplant recipients. Overall transplant recipients have a six fold increase in risk for developing any kind of non-Hodgkin lymphoma and PTLDs occur in up to 10% of SOT recipients. Several new entities have been accepted or renamed in the 2018 update of the WHO classification of tumors of hematopoietic and lymphoid neoplasms, including florid follicular hyperplasia and extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT-lymphoma) (excluding common locations such as stomach and salivary gland)...
March 3, 2018: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/29609086/primary-central-nervous-system-hodgkin-lymphoma-like-post-transplant-lymphoproliferative-disorder
#9
Yusuke S Hori, Keina Nagakita, Yuki Ebisudani, Mizuho Aoi, Toru Fukuhara, Yoko Shinno
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a rare condition occurring after organ transplantation. PTLD comprises four subtypes, of which Hodgkin lymphoma (HL)-type and HL-like type (currently included in polymorphic type) account for only about 1%-3% of cases. Primary central nervous system PTLD is also rare, and most cases are Epstein-Barr virus-positive, B-cell PTLD, while no case of HL-like PTLD has yet been documented. CASE DESCRIPTION: We present a 43-year-old woman who underwent kidney transplantation for IgA nephropathy 14 years previously, and who presented to our Emergency Department with a chief complaint of seizure...
March 30, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29593873/post-transplant-lymphoproliferative-disorder-of-the-bladder-in-a-lung-transplant-recipient
#10
Harpreet Singh Grewal, Charles Lane, Kristin B Highland, Olufemi Akindipe, Marie Budev, Atul C Mehta
Post-transplant lymphoproliferative disorder (PTLD) occurs in ~5% of solid organ and hematopoietic stem cell transplant recipients. We report a unique presentation of PTLD in the bladder of a lung transplant recipient. Our patient was a 62-year-old female who received a bilateral lung transplant for chronic obstructive pulmonary disease. She presented with fever, left-sided flank pain and foul-smelling urine consistent with urosepsis. An abdominal and pelvic computerized tomography revealed an irregular and nodular bladder wall thickening suspicious for urothelial neoplasm...
March 2018: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/29580864/epstein-barr-virus-dnaemia-monitoring-for-the-management-of-post-transplant-lymphoproliferative-disorder
#11
Amit Kalra, Cameron Roessner, Jennifer Jupp, Tyler Williamson, Raymond Tellier, Ahsan Chaudhry, Faisal Khan, Minakshi Taparia, Victor H Jimenez-Zepeda, Douglas A Stewart, Andrew Daly, Jan Storek
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of allogeneic hematopoietic cell transplantation (HCT). Epstein-Barr virus (EBV) reactivation (detectable DNAemia) predisposes to the development of PTLD. METHODS: We retrospectively studied 306 patients monitored for EBV DNAemia after Thymoglobulin-conditioned HCT to determine the utility of the monitoring in the management of PTLD. DNAemia was monitored weekly for ≥12 weeks post-transplantation...
March 23, 2018: Cytotherapy
https://www.readbyqxmd.com/read/29579330/impact-of-the-posttransplant-lymphoproliferative-disorder-subtype-on-survival
#12
Jean L Koff, Jing-Xia Li, Xinyan Zhang, Jeffrey M Switchenko, Christopher R Flowers, Edmund K Waller
BACKGROUND: Posttransplant lymphoproliferative disorder (PTLD) is a life-threatening complication of solid organ transplantation. Histologic heterogeneity and a lack of treatment standards have made evaluating clinical outcomes in specific patient populations difficult. This systematic literature review investigated the impact of the PTLD histologic subtype on survival in a large data set. METHODS: Case series were identified on PubMed with the search terms post-transplant lymphoproliferative disorder/disease, PTLD, and solid organ transplantation, with additional publications identified through reference lists...
March 26, 2018: Cancer
https://www.readbyqxmd.com/read/29524534/non-ptld-malignancy-post-hsct-in-patients-with-primary-immunodeficiency-uk-experience
#13
Mohamed Najib Mohamed Unni, Reem Elfeky, Kanchan Rao, Zohreh Nademi, Robert Chiesa, Persis Amrolia, Roderick Skinner, Olga Slater, Austen Worth, Terence Flood, Mario Abinun, Sophie Hambleton, Waseem Qasim, Hubert B Gaspar, Andrew J Cant, Andrew R Gennery, Paul Veys, Mary A Slatter
Secondary malignancy post haematopoietic stem cell transplantation (HSCT) for malignant disorders is well recognized. There are very few published reports on malignancy post HSCT for Primary Immunodeficiency (PID). We report 12 cases of 944 patients, who developed non-PTLD malignancy post-HSCT for PID.
March 7, 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29518251/low-5-year-cumulative-incidence-of-post-transplant-lymphoproliferative-disorders-after-solid-organ-transplantation-in-switzerland
#14
Raphael Steiner, Robert Kridel, Emiliano Giostra, Thomas McKee, Rita Achermann, Nicolas Mueller, Oriol Manuel, Michael Dickenmann, Macé M Schuurmans, Laurence de Leval, Thomas Fehr, Marianne Tinguely, Isabelle Binet, Sergio Cogliatti, Eugenia Haralamvieva, Michael Koller, The Swiss Transplant Cohort Study Stcs, Pierre-Yves Dietrich
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a potentially life-threatening complication of transplantation occurring in the setting of immunosuppression and oncogenic viral infections. However, little is known about the cumulative incidence, histological subtypes, risk determinants and outcome of PTLD in solid organ transplant (SOT) recipients in Switzerland. METHODS: This retrospective observational study investigated adult SOT recipients from two sequential cohorts, the pre-SCTS (Swiss Transplant Cohort Study) series, with data collected from January 1986 to April 2008, and the STCS series, with data collected from May 2008 to December 2014 in Switzerland...
March 8, 2018: Swiss Medical Weekly
https://www.readbyqxmd.com/read/29517815/systematic-review-and-meta-analysis-of-post-transplant-lymphoproliferative-disorder-in-lung-transplant-recipients
#15
Jesse Cheng, Cody A Moore, Carlo J Iasella, Allan R Glanville, Matthew R Morrell, Randall B Smith, John F McDyer, Christopher R Ensor
A systematic review of papers in English on Post-transplant lymphoproliferative disorder (PTLD) in lung transplant recipients (LTR) using MEDLINE, EMBASE, SCOPUS, and Cochrane databases was performed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations were strictly adhered to. Pooled odds ratios (pOR) were calculated from a random-effects model and heterogeneity among studies was quantitated using I2 values. 14 studies published from 2005 to 2015 were included in the meta-analysis...
March 8, 2018: Clinical Transplantation
https://www.readbyqxmd.com/read/29507477/post-transplantation-lymphoproliferative-disorder-with-gastrointestinal-involvement
#16
Faisal Inayat, Ghias Ul Hassan, Ghias Un Nabi Tayyab, Muhammad Wasif Saif
Post-transplantation lymphoproliferative disorders (PTLDs) are lymphoid proliferations or lymphomas that are the second most common tumors in adult transplant recipients. Most cases of PTLD are attributed to Epstein-Barr virus, which induces B-cell proliferation and occurs in the setting of severe immunosuppression after solid organ or bone marrow transplantation. The disorder is seen in 1-3% of liver transplant recipients and has a variable presentation chronology. Herein, we chronicle a case of aggressive B-cell lymphoma (PTLD WHO class-3) presenting with isolated gastrointestinal involvement in an Epstein-Barr virus-negative patient with living-donor liver transplantation, 4 years after receiving the transplant...
March 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29485513/the-changing-epidemiology-of-posttransplant-lymphoproliferative-disorder-in-adult-solid-organ-transplant-recipients-over-30-years-a-single-center-experience
#17
Anthea C Peters, Michael S Akinwumi, Carlos Cervera, Curtis Mabilangan, Sunita Ghosh, Raymond Lai, Marco Iafollo, Karen Doucette, Jutta K Preiksaitis
BACKGROUND: Posttransplant lymphoproliferative disorders (PTLD) are a complication of solid organ transplantation (SOT) associated with Epstein-Barr virus (EBV). METHODS: We analyzed the incidence of and risk factors for PTLD among adult SOT recipients at our center over 30 years (1984-2013). We also compared PTLD incidence before and after a prevention strategy of EBV viral load monitoring in EBV serology mismatched patients was adopted in 2001 (ie transplant era 1 (1983-2001) vs era 2 (2002-13))...
February 26, 2018: Transplantation
https://www.readbyqxmd.com/read/29473271/neutropenia-in-pediatric-heart-transplant-recipients
#18
Kirsten Rose-Felker, Ayesha Mukhtar, Michael S Kelleman, Shriprasad R Deshpande, William T Mahle
Neutropenia has been reported in pediatric heart transplant recipients, but its association with infectious morbidity and mortality is unknown. We sought to determine neutropenia's prevalence and impact on infection, rejection, and survival. A retrospective analysis of pediatric heart transplant recipients from March 2005 to August 2015 was performed. Demographics, medications, infection, and rejection data were collected. Of 142 pediatric heart transplant recipients, 77 (54.2%) developed neutropenia within 4...
February 23, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29467338/tcr-mimic-bispecific-antibodies-targeting-lmp2a-show-potent-activity-against-ebv-malignancies
#19
Mahiuddin Ahmed, Andres Lopez-Albaitero, Dmitry Pankov, Brian H Santich, Hong Liu, Su Yan, Jingyi Xiang, Pei Wang, Aisha N Hasan, Annamalai Selvakumar, Richard J O'Reilly, Cheng Liu, Nai-Kong V Cheung
EBV infection is associated with a number of malignancies of clinical unmet need, including Hodgkin lymphoma, nasopharyngeal carcinoma, gastric cancer, and posttransplant lymphoproliferative disease (PTLD), all of which express the EBV protein latent membrane protein 2A (LMP2A), an antigen that is difficult to target by conventional antibody approaches. To overcome this, we utilized phage display technology and a structure-guided selection strategy to generate human T cell receptor-like (TCR-like) monoclonal antibodies with exquisite specificity for the LMP2A-derived nonamer peptide, C426LGGLLTMV434 (CLG), as presented on HLA-A*02:01...
February 22, 2018: JCI Insight
https://www.readbyqxmd.com/read/29435138/personalized-adoptive-immunotherapy-for-patients-with-ebv-associated-tumors-and-complications-evaluation-of-novel-naturally-processed-and-presented-ebv-derived-t-cell-epitopes
#20
Maren Bieling, Sabine Tischer, Ulrich Kalinke, Rainer Blasczyk, Søren Buus, Britta Maecker-Kolhoff, Britta Eiz-Vesper
Morbidity and mortality of immunocompromised patients are increased by primary infection with or reactivation of Epstein-Barr virus (EBV), possibly triggering EBV+ post-transplant lymphoproliferative disease (PTLD). Adoptive transfer of EBV-specific cytotoxic T cells (EBV-CTLs) promises a non-toxic immunotherapy to effectively prevent or treat these complications. To improve immunotherapy and immunomonitoring this study aimed at identifying and evaluating naturally processed and presented HLA-A*03:01-restricted EBV-CTL epitopes as immunodominant targets...
January 12, 2018: Oncotarget
keyword
keyword
12162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"